Abstract
BackgroundBecause of the lack of biological components that selectively identifies cancer cells and robustly drives therapeutic gene expression, the conventional strategy for cancer gene therapy offers limited control of specificity and efficacy. Consequently, looking for a specific and effective promoter component can help us overcome these limitations.MethodsHere, we transfected the artificially hTERT promoter sequence into cancer cells and kept the specificity of the promoter. Then we used the Dual luciferase reporter gene system to prove the artificial hTERT promoter’s specificity and efficacy. Last, we demonstrated its modularity by replacing the luciferase reporter gene with other cellular functional genes like hBAX.ResultsUsing the Dual luciferase reporter gene system, we have shown that the aritificial hTERT promoter specifically detected bladder cancer cells and significantly enhanced luciferase expression in comparison to the WT-hTERT-renilla luciferase (Rluc) construct. The functional module of artificial hTERT promoter effectively inhibited bladder urothelial carcinoma cell growth and induced apoptosis by regulating the down-stream gene.ConclusionsThis functional module provides a synthetic biology platform for targeting and controlling bladder cancer.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
